Physician profile
Amie E Prough
NPI 1346381159
$930.91
in general payments reported to CMS, 2019-2025
24 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $43.50 · 2021: $122 · 2022: $151 · 2023: $91.78 · 2024: $56.21 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $97.83 | 2019-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Novo Nordisk INC | $90.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.93 | 2025 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $65.94 | 2019 | |
| Corium, LLC | $62.83 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.98 | 2019-2020 | |
| Amgen INC. | $46.76 | 2019 | |
| Pfizer INC. | $39.63 | 2022-2025 | |
| Abbott Laboratories | $38.62 | 2023-2024 | Freestyle Libre 3 |
| Tris Pharma INC | $37.81 | 2025 | Dyanavel Xr, Onyda Xr |
| Exact Sciences Corporation | $35.62 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $34.81 | 2025 | |
| Sanofi-Aventis U.S. LLC | $33.69 | 2023-2025 | |
| Amarin Pharma, INC. | $32.18 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $20.06 | 2021 | |
| Abbvie INC. | $18.47 | 2019 | |
| Dynavax Technologies Corporation | $17.72 | 2022 | |
| Eisai INC. | $16.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2021 | |
| Glaxosmithkline, LLC. | $13.51 | 2025 | Menveo, Bexsero, Pediarix |
| Ultragenyx Pharmaceutical INC. | $13.38 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $12.08 | 2019 | |
| Genentech USA, INC. | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amie Prough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.